![The source and status of each B-cell lymphoma gene. (A) Studies that reported >1 SMG in FL, BL, or DLBCL are summarized according to the method used to identify mutations (Sanger sequencing,27,59 RNA sequencing,51 whole-genome sequencing [WGS],7,12,20,49,54,60 exome,5,6,10,18,19,21,22,33,53,61 panel,31,32,62 or a combination thereof2,14,15,29,63). Studies are also separated by the lymphoma type that was sequenced, with those using a combination of FL and DLBCL grouped in the middle section along with FL-centric studies. Additional details for each study are also provided in supplemental Table 5. The height of each vertical bar is proportional to the number of newly identified SMGs reported by the study. A gene was not counted if it had already been reported in that entity at the time of the study, but a gene may appear more than once if it was reported in multiple entities (eg, FL and DLBCL). Representative examples of genes that are in either Tier 2 or 3 are shown in the middle, adjacent to the corresponding citation. The number of genes originating from each study and their assignment to 1 of the 3 tiers is summarized on the right (B).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/9/8/10.1182_bloodadvances.2022009461/1/blooda_adv-2022-009461-c-gr2.jpeg?Expires=1748889787&Signature=odEHpbcK20za~owoWxGP8bulc~hXcoVKwEx0Qbz8GmdjXdcSMlR~bXL1G37qr3WkhtmkiNR~5K-ET2X-qiBY1-lSpulSsRG4AJT7QNJt4KvxWnS-4rUF3M7FOAMHwUZ-Y8v6UAMmvQc6qjYxwXzbI-wAg3Mk6aCNrMdlvCCs9tMV2z6H2Q12Bs4fxFRJWbXd3WLwaVh4aNdQ2aJNyu5SrDyPEwGe74XtFPO9fvTSlv~91sR1JDV~QMorO7zfxQxOOI5JlcFEdp~TXGkzH3nPe6vBa1b4utfBttjIGmzI~F6Igf2Ln~VzkskhF0YO8sbQFN2zgeHwo8KcKoAXkd15~g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
The source and status of each B-cell lymphoma gene. (A) Studies that reported >1 SMG in FL, BL, or DLBCL are summarized according to the method used to identify mutations (Sanger sequencing,27,59 RNA sequencing,51 whole-genome sequencing [WGS],7,12,20,49,54,60 exome,5,6,10,18,19,21,22,33,53,61 panel,31,32,62 or a combination thereof2,14,15,29,63). Studies are also separated by the lymphoma type that was sequenced, with those using a combination of FL and DLBCL grouped in the middle section along with FL-centric studies. Additional details for each study are also provided in supplemental Table 5. The height of each vertical bar is proportional to the number of newly identified SMGs reported by the study. A gene was not counted if it had already been reported in that entity at the time of the study, but a gene may appear more than once if it was reported in multiple entities (eg, FL and DLBCL). Representative examples of genes that are in either Tier 2 or 3 are shown in the middle, adjacent to the corresponding citation. The number of genes originating from each study and their assignment to 1 of the 3 tiers is summarized on the right (B).
